FDA 483 OBSERVATION · #296 OF 1,945 MOST-CITED
Component identity verification
FDA cited this observation 102 times across 98 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 5.7× the rate of the average FDA-cited firm (44.9% vs 7.8%), across 98 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.
Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.
Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.
Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.
Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.
Drug product component testing is deficient in that at least one specific test to verify the identity of each component is not performed.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →